New Technique Selectively Kills Old Cells, Reduces Signs of Aging in Animal Model

Even if you aren’t elderly, your body is home to agents of senility—frail and damaged cells that age us and promote disease. Now, researchers have developed a molecule that selectively destroys these so-called senescent cells. The compound makes old mice act and appear more youthful, providing hope that it may do the same for us.

“It’s definitely a landmark advance in the field,” says cell and molecular biologist Francis Rodier of the University of Montreal in Canada who wasn’t connected to the study.

“This is the first time that somebody has shown that you can get rid of senescent cells without having any obvious side effects.”

As we get older, senescent cells build up in our tissues, where researchers think they contribute to illnesses such as heart disease, arthritis, and diabetes. In the past, scientists have genetically modified mice to dispatch their senescent cells, allowing the rodents to live longer and reducing plaque buildup in their arteries. Such genetic alterations aren’t practical for people, but researchers have reported at least seven compounds, known as senolytics, that kill senescent cells. A clinical trial is testing two of the drugs in patients with kidney disease, and other trials are in the works.

Previous work has revealed that a combination of the natural product Quercetin with the cancer drug Dasatnib is able to remove some senescent cells, but with poor specificity. Another class of drugs called Bcl inhibitors has proven able to target and destroy senescent cells – including the drug ABT-263. These have known side effects and drawbacks however, and researchers have been searching for better, more accurate ways of killing these cells without harming the rest of the body. While gene directed therapies such as liposomal delivery or RNA based therapeutics could conceivably be an effective therapeutic route, finding a more easily applied pharmacological approach may be more cost effective in the short term.

Cell biologist Peter de Keizer of Erasmus University Medical Center in Rotterdam, the Netherlands, and colleagues were investigating how senescent cells stay alive when they uncovered a different strategy for attacking them. Senescent cells carry the type of DNA damage that should spur a protective protein, called p53, to put them down. Instead, the researchers found that a different protein, FOXO4, latches onto p53 and prevents it from doing its duty.

To counteract this effect, De Keizer and colleagues designed a molecule, known as a peptide, that carries a shortened version of the segment of FOXO4 that attaches to p53. In a petri dish, this peptide prevented FOXO4 and p53 from hooking up, prompting senescent cells to commit suicide. But it spared healthy cells.

“The paper adds a potentially new way to target senescent cells,” says diabetes researcher James Kirkland of the Mayo Clinic in Rochester, Minnesota. He cautions, however, that peptides like the one De Keizer and colleagues developed have their own limitations. The digestive system destroys them, so they can only be delivered through inhalation or an injection–you can’t just swallow a pill, he notes.

Although the molecule did not reduce the number of platelets in either mouse group, killing off large numbers of senescent cells could still trigger a potentially fatal complication sometimes suffered by cancer patients. Moreover, senescent cells foster wound healing, and destroying the cells could impair this ability.

That’s why De Keizer says he and his colleagues plan to move cautiously with their molecule. “I don’t think you should start treating frail people in their 90s.” Instead, he says, they want to determine whether the molecule kills cancer cells, which share some similarities with senescent cells, starting with the brain tumor glioblastoma. If the compound continues to prove safe, they can think about testing the peptide against age-related diseases or even aging itself.

Health News

The largest and most comprehensive analysis to date of the link between aspirin and cancers of the digestive tract has shown that it is associated not only with a significant reduction in the risk of developing bowel cancer but also of several other cancers that almost invariably fatal, such as pancreatic and liver cancers.

A team of researchers has developed specialized antibody-like receptor proteins that they believe could soak up the excess cytokines produced during a cytokine storm. This excessive immune response, sometimes seen in Covid-19 patients, can be fatal.

Working in a mouse model, researchers report that a single stressful event produced quick and long-lasting changes in astrocytes, the brain cells that clean up neurotransmitters after they've communicated information between nerve cells.

Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide. More than half of NSCLC patients die after developing metastases. There are no tests currently that would allow doctors to identify patients where more aggressive therapy could reduce mortality. Researchers at Tulane University have identified a protein on tumor-derived extracellular vesicles that indicates if a NSCLC tumor is likely to metastasize, according to a new study in Science Advances.

The lens of the human eye comprises a highly concentrated protein solution, which lends the lens its great refractive power. Protective proteins prevent these proteins from clumping together throughout a lifetime. A team of scientists from the Technical University of Munich (TUM) has now uncovered the precise structure of the alpha-A-crystallin protein and, in the process, discovered an important additional function.

As a healthy heart ages, it becomes more susceptible to cardiovascular diseases. Though researchers have discovered that relaxin, an insulin-like hormone, suppresses atrial fibrillation (AF), inflammation, and fibrosis in aged rats, the underlying mechanisms of these benefits are still unknown. Researchers discuss how relaxin interacts with the body's signaling processes to produce a fundamental mechanism that may have great therapeutic potential.

A ketogenic diet produces health benefits in the short term. As the body burns ketone bodies as an alternative source of fuel, tissue-protective gamma delta T-cells expand throughout the body, but negative effects appear after about a week, researchers found in a study of mice.

Aging is a dramatic public health issue in the face of the current demographic changes: the proportion of 60 and over in the world's population will almost double by 2050. In this context, a new discovery has just broadened scientific knowledge. Researchers shed light on the mechanisms of senescence, by identifying a key protein associated with aging.